Can a weekly shot tame blood sugar and weight in type 2 diabetes?

NCT ID NCT07732218

Completed Disease control Sponsor: Rehman Medical Institute - RMI Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial investigates whether a once-weekly injection of semaglutide can improve blood sugar control and reduce body weight in adults with type 2 diabetes and obesity who have not achieved adequate control with standard therapy. Participants receive semaglutide for 16 weeks, starting at a low dose and increasing. The study measures changes in HbA1c, weight, and other health markers, while monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Ozempic), a once-weekly injection
What this could lead to: If successful, this could support semaglutide as an add-on therapy for better blood sugar and weight management in type 2 diabetes.
What could go wrong: This is a small, non-randomized trial without a placebo group, so results may be less reliable. Side effects like nausea or gastrointestinal issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Rehman Medical Institute

Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.